In the usual cancer biopsy, a surgeon cuts out a piece of the patient’s tumor, but researchers in labs across the country are now testing a potentially transformative innovation. They call it the liquid biopsy, and it is a blood test that has only recently become feasible with the latest exquisitely sensitive techniques. It is showing promise in finding tiny snippets of cancer DNA in a patient’s blood.
“Liquid biopsies offer real promise. Sometimes even the tissue biopsy obtained by the surgeon can fail to show the mutation which will predict that a patient will have a good response to a targeted agent. Indeed, liquid biopsies may allow oncologists to predict the emergence of drug resistance even before a tumor grows on x-rays. A formidable new technology,” says Dr. Gregory Curt, Chairman of the T.J. Martell Foundation’s Scientific Advisory Committee.
For the full article in The New York Times, please click here.